Keyphrases
Janus Kinase Inhibitors
100%
Tofacitinib
100%
Psoriasis Treatment
100%
Hematological Parameters
100%
Dose Effect
45%
Placebo
18%
Moderate to Severe
18%
Hematology
18%
Janus Kinase
18%
Cell Count
18%
Chronic Plaque Psoriasis
18%
Treatment Cessation
18%
Hematopoiesis
18%
Monocytes
9%
Blood Samples
9%
White Blood Cells
9%
Neutrophils
9%
Hemoglobin
9%
Partial Inhibition
9%
Compensatory Changes
9%
Off-treatment
9%
Eosinophils
9%
Red Blood Cells
9%
Erythropoiesis
9%
Hematocrit
9%
Neutrophil Count
9%
Reticulocyte Count
9%
Eosinophil Count
9%
Reticulocytes
9%
Non-progressive
9%
Twice Daily
9%
Red Blood Cell Count
9%
Basophils
9%
Natural Killer Cells
9%
Long-term Evaluation
9%
Short-term Administration
9%
Lymphocytes
9%
Lymphocyte Count
9%
B Cells
9%
Cytokine Signaling
9%
Hematological Effects
9%
Hematopoietic Cytokines
9%
Human Hemoglobin
9%
Psoriasis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Tofacitinib
100%
Psoriasis
100%
Janus Kinase Inhibitor
100%
Placebo
18%
Psoriasis Vulgaris
18%
Janus Kinase
18%
Cytokine
9%
Immunology and Microbiology
Tofacitinib
100%
Cell Count
18%
Hematopoiesis
18%
Monocyte
9%
Leukocyte
9%
Basophil Granulocyte
9%
Natural Killer Cell
9%
Lymphocyte Count
9%
Reticulocyte
9%
Hemoglobin Blood Level
9%
Eosinophil Count
9%
Neutrophil Count
9%
Neutrophil Granulocyte
9%
Lymphocyte
9%
Hemocyte
9%
Erythrocyte Count
9%
Erythropoiesis
9%
Hematocrit
9%
B Cell
9%
Eosinophil Granulocyte
9%
Reticulocyte Count
9%
Cytokine Signaling
9%